New cell therapy aims to free kidney transplant patients from insulin dependence

NCT ID NCT06832410

Summary

This study is testing an investigational cell therapy called VX-880 in people who have type 1 diabetes and have already received a kidney transplant. The main goal is to see if the treatment can help participants stop needing insulin injections. Participants must already be on stable anti-rejection medications for their kidney transplant.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology

    RECRUITING

    Riyadh, Saudi Arabia

  • King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology

    RECRUITING

    Riyadh, Saudi Arabia

  • Montefiore Clinical and Translational Research Center - Endocrinology

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • Perelman Center for Advanced Medicine - Endocrinology

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Toronto General Hospital - Endocrinology

    RECRUITING

    Toronto, Canada

  • UW University Hospital - Endocrinology

    RECRUITING

    Madison, Wisconsin, 53792, United States

  • Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre

    RECRUITING

    Vancouver, Canada

Conditions

Explore the condition pages connected to this study.